Portfolio

Aboleris Pharma is a preclinical stage company, developing novel and unique therapeutic approaches to induce immune tolerance while preserving useful immune responses; with the aim to address significant medical unmet needs in patients with inflammatory, autoimmune and degenerative diseases.

ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company’s lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a devastating, rare neuromuscular disorder that causes muscle weakn ...

Teitur is a preclinical stage company, developing novel therapeutics for treating neurodegenerative diseases, including Huntington’s Disease, Parkinson’s Disease and Frontotemporal Dementia. The lead program is a cyclic, lipidated peptide, TT-P34, that target the three major pathophysiological hallmarks of neurodegeneration: mitochondrial failure, ...

VarmX is a clinical stage company developing drugs that reverse the action of direct acting oral anticoagulants (DOACs).The lead program is a recombinant protein, VMX-C001, that addresses the need of a safe and more efficacious antidote against excessive bleeding caused by FXa DOACs.  Location: Leiden, the Netherlands Sound contact:  ...

Breye Therapeutics is a clinical development stage company that developing new therapies within Opthalmology The lead program is Danegaptide – an oral drug that can both treat Diabetic Retinopathy and prevent disease progression. Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascu ...

Artax Biopharma is a clinical stage biotechnology company that develops novel treatments for autoimmune diseases. The lead product, AX-158, is a first-in-class, oral small molecule that inhibits Nck’s binding to the T cell receptor (TCR).  Through this novel mechanism, it selectively modulates Nck’s amplification of the TCR signal, resulting i ...